Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LFCR
STRONG SELLLifecore Biomedical, Inc. · Healthcare · United States · $162M · Avg Vol: $888K/d
COMPANY DESCRIPTION
Lifecore Biomedical, Inc. is a fully integrated cGMP manufacturer and supplier of fermentation-derived hyaluronic acid (HA), and a contract development and manufacturing organization (CDMO) for sterile fill-finish pharmaceuticals. The company is a leading provider of high-quality HA, benefiting from expertise in fermentation processes and a strong reputation as a CDMO for complex injectable products. Lifecore Biomedical is a vertically integrated biomedical company specializing in hyaluronic acid production and sterile pharmaceutical manufacturing.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111.3M | 103.3M | 128.3M | — | 7.4% | 129.5M | 122.2M | 130.2M | 0.5% |
| EPS | -3.29 | -3.41 | 0.40 | — | — | -1.28 | -1.04 | -0.98 | — |
| Shares | — | 29.5M | 30.6M | 37.5M | +27.0% | 37.5M | — | — | — |
| Debt | — | 112.6M | 128.6M | 142.6M | 12.5% | 150.1M | — | — | — |
| Equity | — | -4.2M | 11.3M | -14.2M | — | — | — | — | — |
| Op CF | -22.6M | -17.4M | 0.3M | — | — | 12.6M | — | — | — |
| Inv CF | 80.0M | -4.8M | -18.4M | — | — | — | — | — | — |
| Fin CF | -57.0M | 39.7M | 7.5M | — | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LFCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LFCR | Lifecore Biomedical, Inc.(you) | $162M | 13 | STRONG SELL |
| DERM | Journey Medical Corporation | $170M | 24 | SELL |
| CWEB.TO | Charlotte's Web Holdings, Inc. | $67M | 16 | STRONG SELL |
| TLPH | Talphera, Inc. | $70M | 22 | SELL |
| AQST | Aquestive Therapeutics, Inc. | $462M | 18 | STRONG SELL |
| AKBA | Akebia Therapeutics, Inc. | $327M | 30 | SELL |
| JUSH.CN | Jushi Holdings Inc. | $83M | 31 | SELL |
| TKNO | Alpha Teknova, Inc. | $266M | 37 | HOLD |
| GRIN.CN | Grown Rogue International Inc. | $109M | 39 | HOLD |
| CTOR | Citius Oncology, Inc. | $52M | 2 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%